Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Eptifibatide · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Eptifibatide | EXPERIMENTAL | Eptifibatide in addition to standard of care such as standard doses of aspirin, unfractionated heparin or low-molecular-weight heparin. |
| Placebo | PLACEBO_COMPARATOR | Placebo in addition to standard of care such as standard doses of aspirin, unfractionated heparin or low-molecular-weight heparin. |
| Name | Type | Description |
|---|---|---|
| Eptifibatide (Integrilin) | DRUG | intravenous; 180 mcg/kg bolus followed by infusion of 2 mcg/kg/min for 12 to 96 hours (or longer if necessary to complete the 18- to 24-hour post-PCI infusion period, or up to 120 hours in patients who proceed to CABG \[coronary artery bypass graft\]); second bolus of 180 mcg/kg administered 10 minutes after first bolus. |
| Placebo | DRUG | intravenous; delivery to match eptifibatide to maintain blind |
Inclusion Criteria: * Willing and able to give informed consent and comply with study procedures and follow-up through 1 year. * Plan to undergo an invasive strategy after receiving study drug for 12 to 96 hours. * Able to be randomized into the trial within 12 hours of having symptoms of acute cor...
Eptifibatide is a small molecule being studied for the treatment of Myocardial Ischemia, specifically in patients with non-ST-segment elevation acute coronary syndrome. It is currently in Phase 3 clinical development and is not yet approved for this indication.
Eptifibatide targets the glycoprotein IIb/IIIa receptor on platelets. By inhibiting this receptor, it prevents platelet aggregation, which is a key step in the formation of blood clots that can lead to myocardial ischemia and acute coronary syndromes.
Eptifibatide is being developed by Organon & Co., a company listed on the New York Stock Exchange under the ticker symbol OGN. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with myocardial ischemia.
Eptifibatide is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities for the treatment of myocardial ischemia. The Phase 3 trial has been completed, and the results will determine its future development.
Eptifibatide has one completed Phase 3 clinical trial registered as NCT00089895, known as the EARLY ACS study. This trial enrolled 9,406 patients with non-ST-segment elevation acute coronary syndrome and was a randomized, double-blind, placebo-controlled study.
Eptifibatide is also known by the brand name Integrilin. It is a glycoprotein IIb/IIIa inhibitor used to prevent platelet aggregation in patients with acute coronary syndromes, including those undergoing percutaneous coronary intervention.